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ABSTRACT: Molecular recognition is a complex process that involves a large
ensemble of structures of the receptor and ligand. Yet, most structure-based virtual
screening is carried out on a single structure typically from X-ray crystallography.
Explicit-solvent molecular dynamics (MD) simulations oﬀer an opportunity to
sample multiple conformational states of a protein. Here we evaluate our recently
developed scoring method SVMSP in its ability to enrich chemical libraries docked
to MD structures of seven proteins from the Directory of Useful Decoys (DUD).
SVMSP is a target-speciﬁc rescoring method that combines machine learning with
statistical potentials. We ﬁnd that enrichment power as measured by the area under
the ROC curve (ROC-AUC) is not aﬀected by increasing the number of MD
structures. Among individual MD snapshots, many exhibited enrichment that was
signiﬁcantly better than the crystal structure, but no correlation between
enrichment and structural deviation from crystal structure was found. We followed
an innovative approach by training SVMSP scoring models using MD structures (SVMSPMD). The resulting models were applied
to two diﬃcult cases (p38 and CDK2) for which enrichment was not better than random. We found remarkable increase in
enrichment power, particularly for p38, where the ROC-AUC increased by 0.30 to 0.85. Finally, we explored approaches for
a priori identiﬁcation of MD snapshots with high enrichment power from an MD simulation in the absence of active compounds.
We found that the use of randomly selected compounds docked to the target of interest using SVMSP led to notable enrichment
for EGFR and Src MD snapshots. SVMSP rescoring of protein−compound MD structures was applied for the search of small-
molecule inhibitors of the mitochondrial enzyme aldehyde dehydrogenase 2 (ALDH2). Rank-ordering of a commercial library of
50 000 compounds docked to MD structures of ALDH2 led to ﬁve small-molecule inhibitors. Four compounds had IC50s below
5 μM. These compounds serve as leads for the design and synthesis of more potent and selective ALDH2 inhibitors.
■ INTRODUCTION
Structure-based virtual screening is widely used in the search
for small molecules to probe the function of proteins and
nucleic acids in chemical biology and drug discovery.1,2
Typically, a chemical library is docked to a pocket on the
target structure, followed by the ranking of the resulting
protein−compound complexes in a process known as scoring.
The top candidates are acquired or prepared for experimental
validation. Several scoring methods have been developed over
the years; these include empirical,3−11 knowledge-based,12−21
and force ﬁeld-based.22−29 We recently developed a new
scoring approach that combines machine learning and statistical
knowledge-based potentials for rank-ordering Support Vector
Regression Knowledge-Based (SVRKB)30 and database enrich-
ment Support Vector Machine SPeciﬁc (SVMSP).31 The
former is regression-based and trained on crystal structures
using corresponding experimental binding aﬃnities, while the
latter is based on classiﬁcation and is trained strictly on three-
dimensional structures of protein−ligand complexes using both
actives and decoys.
Part of the challenge with the use of structure-based virtual
screening is protein ﬂexibility.32−34 It is ignored in the majority
of cases by docking compounds strictly to a crystal
structure,35−37 although there are examples that have used
multiple crystal structures,38−40 NMR structures,41−44 or a
combination of the two.45,46 Albeit less common, the use of
molecular dynamics (MD) simulations to generate an ensemble
of structures has also been reported in virtual screening eﬀorts
that have led to active compounds.47−51 Our own recent study
led to the discovery of small-molecule inhibitors of a tight
protein−protein interaction by docking a chemical library to
protein structures collected from explicit-solvent MD simu-
lations.52 Several studies have attempted to gain a deeper
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understanding of the role of MD structures on chemical
database enrichment.33,34,53
Here, we conduct an in-depth study to investigate the
SVMSP scoring approach in chemical database enrichment
using structures collected from explicit-solvent MD simulations.
We explore enrichment for individual and ensembles of
structures. In addition, we follow an innovative approach that
explores the use of MD structures for the development of
scoring functions for virtual screening. Also, we investigate the
a priori identiﬁcation of MD snapshots with high enrichment
power from an MD simulation. Finally, SVMSP scoring of
protein−compound MD structures is applied in the virtual
screening of commercial libraries against the mitochondrial
aldehyde dehydrogenase 2 enzyme (ALDH2). ALDH2
catalyzes the NAD+-dependent oxidation of a broad spectrum
of endogenous and biogenic aldehydes to their corresponding
carboxylic acids. ALDH2 is commonly associated with its role
in alcohol metabolism, but it has been suggested as a potential
target for a variety of diseases that include addiction and cancer.
Top candidates that emerged from virtual screening were
acquired and tested for inhibition of enzyme activity.
■ MATERIALS AND METHODS
Data Set Preparation. For the enrichment study, 7 protein
structure from the Directory of Useful Decoys (DUD)54 and
one from our in-house validation set, namely, MDM2 (mouse
double minute 2 homolog) (PDB code: 1RV1), were used to
assess the performance of scoring functions. The DUD proteins
include acetycholinesterase AChE (PDB code: 1EVE), human
androgen receptor AR (PDB code: 1XQ2), human cyclin-
dependent kinase 2 CDK2 (PDB code: 1CKP), human
epidermal growth factor receptor EGFR (PDB code: 1M17),
human mitogen-activated protein kinase 14 known as p38
(PDB code: 1KV2), human proto-oncogene tyrosine-protein
kinase Src (PDB code: 2SRC), and cationic trypsin (PDB code:
1BJU).
To ensure diversity among the active compounds in DUD,
the compounds were clustered by chemical similarity. FP3
ﬁngerprints were generated for every ligand with Open Babel.55
A Tanimoto coeﬃcient matrix was calculated for each target by
Open Babel. Hierarchical clustering method was applied with
the cluster package in python2.6 to cluster compounds. The
getlevel threshold in the cluster package was set to 0.1, which
means that any two compounds with Tanimoto coeﬃcient
deviation less than 0.1 will be included into the same cluster.
The number of compounds after clustering for each target is
shown in Table 1. The ratio of active ligands to decoys
(Nligands/Ndecoys) was kept to 1:36 following the convention
adopted in DUD.
MD Simulations. Explicit-solvent MD simulations were
carried out for 8 proteins (Table 1). Crystal structures were
obtained from the RCSB Protein Data Bank (PDB).56
Preparation of the structures was performed by adding
hydrogen atoms and modeling missing gaps with BIOPOL-
YMER module in SYBYL 8.0 (Tripos International, St. Louis,
MO, U.S.A.). Water molecules from crystal structures within 5
Å of any atoms on the protein were retained. Residue
orientation and protonation states were further adjusted using
the REDUCE57 program to optimize the hydrogen bonding
network. The structures were immersed in a box of TIP3P58
water molecules. No atom on the protein was within 14 Å from
any side of the box. The solvated box was further neutralized
with Na+ or Cl− counterions using the leap program from the
AMBER9 package.59
MD simulations were performed using the pmemd program
in AMBER9 with ﬀ03 force ﬁeld60 in periodic boundary
conditions. All bonds involving hydrogen atoms were con-
strained by using the SHAKE algorithm.61 The simulations
were carried out using a 2 fs time step. The particle mesh Ewald
(PME) method was used to treat long-range electrostatics.
Simulations were run at 298 K under 1 atm in the NPT
ensemble employing Langevin thermostat and Berendsen
barostat. Water molecules were ﬁrst energy-minimized and
equilibrated by running a short simulation with the complex
ﬁxed using Cartesian restraints. A series of energy minimiza-
tions were subsequently carried out where the Cartesian
restraints were gradually relaxed from 500 to 0 kcal·Å−2, and
the system was subsequently gradually heated to 298 K via a 48
ps MD run. For each target, four independent 6 ns simulations
were performed. MD snapshots were collected every 1 ps
yielding 6 000 structures per trajectory, or 24 000 structures in
total.
The ﬁrst 1 ns for each trajectory was discarded for
equilibration. A set of 500 snapshots was extracted at regular
intervals from the resulting 20 000 snapshots for each protein.
Atoms within 5 Å around the ligand in the crystal structure
were considered as pocket atoms. The 500 trajectory frames
were further clustered into groups based on pairwise similarity
measured by root-mean-square deviation (RMSD) of pocket
atoms with the ptraj program in AMBER. The hierarchical
clustering algorithm was used to cluster all 500 structures into
sets of 5, 10, 20, 30, 50, 100, and 250 structures.
Scoring Protein−Ligand Complexes. We previously
reported the SVMSP scoring approach31 for enriching
databases. SVMSP is speciﬁcally developed for each target
protein. The SVMSP model was built by using protein−ligand
crystal structures from the sc-PDB database (v2010)62 for the
positive set and randomly selected compounds docked to the
target of interest as the negative set. The positive set was
reﬁned by removing crystal structures in which the ligand
contained highly charged moieties such as sulfate or phosphate
groups, resulting in a set of 4677 structures. Full names and
PDB codes of the crystal structure are provided in the
Supporting Information. The negative set consisted of 5000
randomly selected compounds from the ChemDiv library
docked to a pocket within the target of interest. The
SVMSPKINASE model was developed for kinase targets only.
The positive set included only kinase structures from the sc-
PDB database, consisting of 763 crystal structures. The negative
set for SVMSPKINASE was the same as the SVMSP model.
SVMSPMD models were created by using decoy compounds
docked to MD snapshots for the negative training set. A total of
Table 1. Validation Set for Enrichment Studies
target
protein
number of ligands in
DUD
number of ligands after
clustering
number of
decoys
AChE 105 18 648
AR 74 18 648
CDK2 50 27 972
EGFR 444 33 1188
MDM2 19 19 684
p38 256 31 1116
Src 162 21 756
trypsin 44 15 540
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5000 randomly selected compounds were docked to each MD
snapshot. The positive set consisted of the same structures that
were used to develop SVMSP. When the positive set employed
kinase-only structures, the model was called SVMSPKINASE‑MD.
To develop the SVMSP models, we extended on our
previous work by using 14 distinct protein atom types and 16
ligand atom types (Supporting Information Table S1).31 This
resulted in 224 atom pairs. We used 76 pair potentials for the
vectors of SVMSP. A higher SVMSP score corresponds to a
higher probability that the compound is an active compound.
Compounds Docking. All the molecular docking reported
in this work was done using Autodock Vina.63 The
exhaustiveness parameter of the Vina program was set to the
default value of 8. A maximum number of 9 binding modes
were generated, with maximum energy diﬀerence between the
best and worst binding mode set to 3 kcal·mol−1. The docking
pose with the lowest energy estimated by Vina was selected as
the best binding pose for further scoring. The box size was 19
Å.
ROC and Statistical Analysis. A tool that is commonly
used to assess the performance of a scoring function is the
receiver operating characteristic (ROC) plot.64 An ROC curve
is constructed by ranking the docked complexes, selecting a set
of compounds starting from the highest scoring compounds,
and counting the number of active compounds. This process is
repeated a number of times for a gradually increasing set of
compounds selected from the ranked list. In an ROC plot, the
farther away the curve is from the diagonal, the better the
performance of the scoring function. The area under the ROC
curve, which we refer to as ROC-AUC, can also be used as a
representation of the performance of the scoring function. A
perfect scoring function has an ROC-AUC of 1, while a random
classiﬁcation will have an ROC-AUC of 0.5.
ALDH2 Virtual Screening. The initial coordinates of
ALDH2 used in the molecular dynamics (MD) simulations
were obtained from the PDB (PDB code: 1O04). The PDB ﬁle
was imported into Maestro (version 9.3, Schrödinger, LLC,
New York, NY, 2012), prepared using the Protein Preparation
Wizard.65 Bond orders were assigned, hydrogen atoms were
added, disulﬁde bonds were created, and selenomethionines
were converted to methionines. Crystal water molecules were
kept. MD simulations were carried out as described above. By
assigning diﬀerent initial velocities, ﬁve independent 7 ns
simulations were carried out for a total length of 35 ns
simulation. The ﬁrst 2 ns of each trajectory were considered as
part of the equilibration process and discarded. MD snapshots
were saved every 1 ps yielding 5000 structures per trajectory. In
total, 25 000 snapshots were collected. The snapshots were
clustered into 75 sets using the ptraj program using atoms
around the active site pocket. The hierarchical clustering
algorithm was used for the clustering. Among 75 clusters, the
top 50 clusters that had the most snapshots were selected. A
representative snapshot was chosen for virtual screening from
each of the 50 clusters. Around 50 000 compounds from
ChemDiv8066 library were docked to each of the 50 snapshots
using Vina.
Docked receptor−ligand complexes were rescored using
SVMSP. The 5000 randomly picked compounds from
ChemDiv library docked to ALDH2 crystal structure were
used as the negative set to build the SVMSP model. For each
compound, the highest score among all the snapshots within
the cluster was used to rank all the compounds. Top scored
5000 compounds from the ChemDiv80 library were selected.
Canvas similarity and clustering scripts67,68 in the Maestro
program were applied to cluster the top compounds. Atom
triplet ﬁngerprint type with 32-bit precision was used. Atom
typing scheme was the Daylight invariant atom types. The
single linkage method was used to generate 150 clusters. The
compounds representing the 150 cluster center were selected
for further experimental validation.
ALDH Inhibition Assays. Compounds were ﬁrst screened
using a high-throughput dehydrogenase assay to measure the
production of NADH via ﬂuorescence (excitation λ = 340 nm,
emission λ = 465 nm) on an Ultra384 plate reader over a 10
min period. The screening assay used 20 nM ALDH2, 30 μM
propionaldehyde, 100 μM NAD+, and 50 μM compound in 25
mM BES, pH 7.5 with 2% (v/v) DMSO in a 96-well black plate
with a ﬁnal volume of 200 μL. The compounds that showed
inhibition in this assay were then tested for their eﬀect on
ALDH2 dehydrogenase activity at 50 μM concentration using a
Beckman DU-640. The dehydrogenase assay used 150 nM
ALDH2, 100 μM propionaldehyde, and 200 μM NAD+ in 25
mM BES, pH 7.5 with 1% (v/v) DMSO. The assays were
monitored at 340 nm for the increase in NADH production
(extinction coeﬃcient = 6.22 mM−1 cm−1). If compounds
showed inhibition at this concentration, assays to determine the
concentration dependence of inhibition (IC50) were performed.
IC50 values toward inhibition of ALDH2 activity were
measured with compound concentrations ranging from 0 to
100 μM. All IC50 values were determined by ﬁtting to the 4-
parameter logistics function in SigmaPlot (v12).
■ RESULTS
Enrichment in the Conformational Ensemble. We were
particularly interested in assessing how our scoring approach,
SVMSP, aﬀects enrichment of compound libraries docked to
MD structures collected from explicit-solvent MD simulations.
To that end, MD simulations were carried out for 8 proteins
that included 7 proteins from the Directory of Decoys (DUD),
namely, androgen receptor (AR), acetylcholinesterase (AChE),
trypsin, cyclin-dependent kinase 2 (CDK2), epidermal growth
factor receptor (EGFR), mitrogen-activated protein kinase
Table 2. SVMSP Enrichment Performance of Diﬀerent Cluster Size
AChE AR CDK2 EGFR MDM2 p38 Src trypsin
crystal 0.66 0.82 0.60 0.90 0.82 0.38 0.80 0.85
5 0.65 0.82 0.60 0.92 0.73 0.35 0.73 0.93
10 0.62 0.82 0.54 0.90 0.76 0.37 0.72 0.93
20 0.77 0.81 0.57 0.75 0.76 0.37 0.76 0.96
30 0.68 0.82 0.60 0.77 0.74 0.37 0.73 0.96
50 0.72 0.82 0.55 0.90 0.75 0.36 0.79 0.96
100 0.76 0.83 0.57 0.88 0.77 0.33 0.75 0.96
250 0.78 0.82 0.57 0.90 0.76 0.33 0.76 0.96
Journal of Chemical Information and Modeling Article
dx.doi.org/10.1021/ci5002026 | J. Chem. Inf. Model. 2014, 54, 2105−21162107
(p38), and proto-oncogene protein tyrosine kinase (Src). One
additional protein, MDM2, which is involved in a protein−
protein interaction with p53, was added to the list (Table 1). A
total of 24 ns of simulation was carried out for each protein. In
each case, a set of 500 structures were collected at regular
intervals from 20 000 snapshots generated by the simulations.
Decoy and active compounds obtained from DUD (or
generated for MDM2) were docked to the 500 MD snapshots
with AutoDock Vina. The resulting complexes were scored with
SVMSP,31 ChemScore,69 GoldScore,70 and GBSA.71
First, we investigated how the total number of MD structures
in the ensemble aﬀect enrichment. The 500 MD snapshots for
each protein in Table 1 were clustered into sets containing 5,
10, 20, 30, 50, 100, and 250 MD structures. Compounds were
ranked using the highest score among all the MD snapshots to
which the compound was docked (Table 2). For the crystal
structures, the ROC-AUC ranged from 0.38 for p38 to 0.90 for
EGFR. The ROC-AUC for SVMSP was larger than 0.8 for ﬁve
out of the eight proteins. For MD structures, there were two
cases, trypsin and AChE, which showed a gradual increase in
the ROC-AUC as the size of the cluster became larger (Figure
1). In the case of trypsin, the ROC-AUC nearly reached a value
of 1 for the cluster for 250 structures. For AChE, an
improvement of nearly 0.1 in ROC-AUC was observed when
compared to the crystal structure. In the case of p38 kinase,
CDK2, and AR, the performance remained constant at 0.33,
0.57, and 0.82, respectively. Src reveals an initial drop in ROC-
AUC of about 0.1 units to 0.7, which does not change as the
number of structures is increased. For EGFR, the ROC-AUC
was constant for 5 and 10 snapshots but dropped by 0.2 units
for 20 and 30 structures only to show an increase back to 0.9
for 50, 100, and 250 structures. The results suggest that a
cluster of 50 snapshots is likely to result in the best
performance across a set of diverse proteins for SVMSP. All
data presented below uses the 50 MD snapshots unless
otherwise stated.
Enrichment performance for the other three scoring
functions, namely, GoldScore, ChemScore, and GBSA, were
poor in all systems when the crystal structure was used. ROC-
AUCs do not change signiﬁcantly in all four scoring functions
with respect to the size of the cluster (Figure 1 and Supporting
Information Table S2). For ChemScore, GoldScore, and GBSA
rescoring, performance is similar to the crystal structure in each
cluster. An exception is for GBSA in AR where a drop from 0.7
to 0.4 is observed.
Enrichment for Individual Snapshots. The docking of all
actives and decoys to 500 snapshots collected from the MD
simulations of each protein in Table 1 provided an opportunity
to explore enrichment for individual MD structures. ROC-AUC
scores were determined for all 500 snapshots collected for each
of the 8 target proteins in Table 1. The ROC-AUC for each
snapshot was plotted against its structural deviation from the
crystal structure measured by the root-mean-square derivation
(RMSD) (Figure 2). No direct correlation between ROC-AUC
and RMSD is observed. This suggests that greater overall
structural deviation from the crystal structure does not translate
into lower or higher enrichment performance (Figure 2).
What is notable from this data is the large ﬂuctuation in the
ROC-AUC among the 500 snapshots. Enrichment in several
MD snapshots exceeded that of the corresponding crystal
structure (Table 3). A total of 32, 55, 2, 81, 17, 76, 13, and 18%
of the snapshots for AChE, AR, MDM2, p38, trypsin, EGFR,
CDK2, and Src, respectively, exhibited better performance than
the crystal structure. In some cases, there exist MD snapshots
that signiﬁcantly exceeded the enrichment power of the crystal
structure (Table 3). For example, for AChE, the snapshot with
the maximum ROC-AUC (ROC-AUCMAX) was 0.83, nearly 0.2
higher than the crystal structure. A similar snapshot was
identiﬁed for AR (ROC-AUCMAX = 0.90), CDK2 (ROC-
AUCMAX = 0.77), EGFR (ROC-AUCMAX = 0.97), MDM2
(ROC-AUCMAX = 0.85), trypsin (ROC-AUCMAX = 0.94), and
Src (ROC-AUCMAX = 0.74). Two proteins, namely, p38 and
Figure 1. ROC-AUC scores for diﬀerent clusters of MD structures. (A) SVMSP; (B) ChemScore; (C) GoldScore; and (D) GBSA.
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CDK2, had poor enrichment both in the crystal (ROC-AUC of
0.38 and 0.60, respectively) and MD structures (ROC-AUC of
0.36 and 0.55, respectively). For these two proteins, ROC-
AUCMAX was 0.54 and 0.77, respectively.
Training SVMSP with MD Structures. Our SVMSP
models have been developed entirely using protein−compound
cocrystal structures (positive set) and compounds docked to
the target crystal structure (negative set). We explored the
possibility of using MD structures to develop SVMSP scoring
models. To accomplish this, we followed the same protocol for
developing the SVMSP models except that compounds in the
negative set were docked to MD snapshots of the target of
interest. We continued to use cocrystal structures for the
positive set. The resulting SVMSP models (SVMSPMD) were
tested on all 500 snapshots for two targets, namely, p38 and
CDK2. These targets were selected because of the poor
enrichment that was observed in both X-ray and MD structures.
A remarkable increase in the ROC-AUC for SVMSPMD was
observed for p38, from 0.42 to 0.64 (Figure 3A and Table 3).
ROC-AUCMAX was 0.81, compared to 0.54 using the crystal
structure. A similar increase in performance was observed for
CDK2 by 0.10. The mean ROC-AUC is 0.62, compared with
0.54 for SVMSP trained strictly with crystal structures. In fact,
more than 29 snapshots were found to have an ROC-AUC
Figure 2. ROC-AUC for individual snapshots. Green line represents ROC-AUC using single crystal structure, and blue line represents ROC-AUC
using 50 clustered MD snapshots.
Table 3. SVMSP Enrichment Performance for 500 MD Snapshots
ROC-AUC scoring method AChE AR CDK2 EGFR MDM2 p38 Src trypsin
crystal structure SVMSP 0.66 0.82 0.60 0.90 0.82 0.38 0.80 0.85
ROC-AUCMIN SVMSP 0.48 0.56 0.35 0.67 0.56 0.32 0.46 0.58
ROC-AUCMAX SVMSP 0.83 0.90 0.77 0.97 0.85 0.54 0.89 0.94
range SVMSP 0.35 0.34 0.42 0.30 0.29 0.22 0.44 0.36
mean SVMSP 0.63 0.82 0.54 0.92 0.72 0.42 0.74 0.79
ROC-AUCMIN SVMSPMD - - 0.44 - - 0.50 - -
ROC-AUCMAX SVMSPMD - - 0.77 - - 0.81 - -
range SVMSPMD - - 0.33 - - 0.31 - -
mean SVMSPMD - - 0.62 - - 0.64 - -
ROC-AUCMAX SVMSPKINASE‑MD - - 0.81 - - 0.85 - -
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greater than 0.70 for SVMSPMD in contrast to only one
snapshot with the standard SVMSP approach. We also
developed SVMSPKINASE‑MD model applied using strictly kinase
cocrystal structures for the positive set. An improvement in the
mean ROC-AUC is observed in both cases by nearly 0.05 over
SVMSPMD (Figure 3). In addition, a signiﬁcantly greater
number of snapshots with ROC-AUC greater than 0.70 were
identiﬁed (6% for SVMSPMD versus 20% for SVMSPKINASE‑MD).
The maximum ROC-AUC also increased by 0.05 relative to
SVMSPMD (Table 3).
A Priori Selection of MD Snapshots with High
Enrichment Power. The aforementioned results show that a
subset of MD snapshots possess greater enrichment power than
the crystal structure. A question of interest is whether one can
preselect these MD structures from an MD simulation of the
apo structure in the absence of actives. Our set of protein−
compound structures enable us to address this question since
we know the enrichment power of each snapshot. The ROC-
AUC can be used as a score to rank-order the snapshots.
A plot of ROC-AUC for each snapshot of the proteins in
Table 1 reveals that MD snapshots with higher enrichment
power have a tendency to have lower average SVMSP scores for
negative set compounds (Supporting Information Figure S1).
Hence, to identify MD snapshots with high enrichment power,
one could dock randomly selected compounds to the snapshots
and rank the snapshots with SVMSP. The snapshots with the
lowest SVMSP scores are likely to have the highest enrichment
power (least likely to bind to the random compounds). To test
this we docked a set of randomly selected compounds to each
of the 500 snapshots of EGFR and Src. These compounds were
scored with SVMSP, and a median decoy score was determined
for SVMSP. In each case, snapshots were ranked with the
median SVMSP score. To determine how eﬀectively we are
ﬁltering these MD snapshots for structures with high
enrichment power, we deﬁned ROC-AUC thresholds of 50,
60, 70, 80, and 90% of the ROC-AUC range (ROC-AUCMAX −
ROC-AUCMIN) score (Figure 4). So a 50% threshold means
that if an MD snapshot has an ROC-AUC that is greater than
50% of the value of the maximum ROC-AUC minus the
minimum ROC-AUC, it is considered a true positive. This
threshold enabled us to construct ROC curves to test how
eﬀectively we are enriching for snapshots that exceed this
threshold. In the case of EGFR, assuming a 50% threshold, the
ability to a priori identify high enrichment structures is high as
evidenced by an ROC-AUC of 0.90 (Figure 4). When a more
stringent deﬁnition is used for high enrichment power (90% of
the ROC-AUC of the crystal structure), the a priori
identiﬁcation of high enrichment power MD structures
becomes more challenging as evidenced by a decrease in the
ROC-AUC to 0.63. For Src, a similar performance is found
with ROC-AUC of 0.71 for a 50% threshold but less signiﬁcant
enrichment was obtained (0.76) using a 90% threshold.
Rank-Ordering in Crystal and MD Structures. While
ROC-AUC data gave a measure of enrichment, it did not
provide insight into the rank-ordering of compounds among
MD snapshots. Rank-ordering was compared for MD structures
using Kendall’s τ. The correlation metric is a measure of rank
correlation, which provides insight into the similarity of the
ordering of the data. The correlation coeﬃcient ranges from −1
(anticorrelated) to 1 (correlated). We used τ to compare the
Figure 3. ROC-AUC for individual snapshots using SVMSP trained
with MD structures. (A) p38 and (B) CDK2. Blue, black, red, and
green lines correspond to the ROC-AUC score of crystal structure by
SVMSP model, and average ROC-AUC scores of MD snapshots by
the SVMSP model, SVMSPMD model, and SVMSPKINASE‑MD model,
respectively.
Figure 4. Filtering MD snapshots for a priori identiﬁcation of high
enrichment structures. ROC curves for (A) EGFR and (B) Src protein
kinases. Black, red, green, yellow, blue, and magenta curves cutoﬀs that
correspond to crystal structure, 50, 60, 70, 80, and 90% of ROC-AUC
range deﬁned as ROC-AUCMAX − ROC-AUCMIN. The number in the
legend is the ROC-AUC for each threshold.
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rank-ordering of the X-ray and 50 MD snapshot to each other.
The data is illustrated in a 2D color-coded map in Figure 5. The
maps reveal that changes in the rank-ordering among structures
can vary substantially from one protein to the other. In the case
of AChE and trypsin, for example, there was little similarity in
the ordering of the compounds from snapshot to snapshot as
evidenced by the relatively low τ values (Figure 5). In fact,
there was a higher tendency for the rank-ordering to be
anticorrelated. Src, CDK2, and MDM2, on the other hand,
showed less anticorrelation than AChE and trypsin. But the
three proteins had more pronounced ﬂuctuation in their rank-
ordering. Two targets, p38 and EGFR, revealed even higher τ
values (greater than 0.5), suggesting less eﬀect of conforma-
tional change on the binding of compounds. Finally, rank-
ordering of AR was the least sensitive to changes in the
structure of the protein as evidenced by τ values exceeding 0.6
in the majority of structures. Figure 5I shows τ comparing the
rank-ordering in the crystal structure versus all the 50
snapshots. Interestingly, the correlation trends show similarity
with correlation among MD snapshots. AR was the only case
that showed a strong correlation between the ordering of
compounds in the X-ray and MD structures. MDM2 snapshots
showed the highest similarity in the ordering of compounds
with one snapshot that had very similar correlation with the X-
ray structure of the protein. AChE snapshots were the least
similar to the X-ray structure of the protein.
Overall, it was interesting that the ordering of compounds
among MD structures did not correlate with enrichment
performance. For example, the ROC-AUC in p38 was relatively
poor compared to EGFR (0.36 and 0.90, respectively), but they
both showed similar 2D maps in Figure 5. Conversely, ROC-
AUC values were relatively similar in AChE and MDM2 (0.72
and 0.75, respectively), but their similarity maps were
dramatically diﬀerent.
Virtual Screening Chemical Library against MD
Structures Leads to ALDH2 Small-Molecule Inhibitors.
We applied SVMSP rescoring of MD structures to the aldehyde
dehydrogenase 2 (ALDH2) enzyme using SVMSP as the
Figure 5. Correlation in the rank-ordering of compounds between diﬀerent structures using Kendall’s τ for (A) AchE; (B) AR; (C) MDM2; (D)
p38; (E) trypsin; (F) EGFR; (G) CDK2; (H) Src; and (I) correlation between crystal structure (x-axis) and 50 MD clustered MD snapshots (y-
axis). From left to right: AchE, AR, MDM2, p38, trypsin, EGFR, CDK2, and Src. Color coding varies from τ = −0.4 (blue) and τ = 1.0 (red).
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scoring approach. The crystal structure of ALDH2 in its apo
form (PDB code: 1O04) was used to carry out explicit-solvent
unbiased MD simulations.72−75 Five independent simulations
with 7 ns in length (35 ns total) yielded 25 000 snapshots.
These were clustered by RMSD using ptraj76 as described
above. A set of 50 representative snapshots were selected from
the clusters. A focused set of the ChemDiv commercial library66
containing 50 000 compounds were docked to each of the 50
snapshots by AutoDock Vina.63 Docked receptor−ligand
complexes were rescored with SVMSP. For each of the 50
000 compounds, the 50 MD snapshots to which they were
docked were ranked and the top score was selected. The scores
were used to rank the 50 000 compounds. The top 1000
compounds were clustered into 150 sets that led to the
selection of a representative compound from each set. Among
the 150 compounds, 111 were commercially available and
purchased for screening. A dehydrogenase assay that we have
previously developed77 was used to screen all 111 compounds
at an initial concentration of 50 μM (Figure 6A). Compounds
that inhibited ALDH2 dehydrogenase activity by more than
50% were selected for a follow-up concentration dependent
study. Among them, ﬁve compounds inhibited the enzyme in a
concentration-dependent manner (Figure 6B). The IC50s were
2.32, ∼23, 0.62, 1.58, and 3.51 for ALDH400, ALDH417,
ALDH423, ALDH427, and ALDH440, respectively (Figure
6C).
Three compounds had some structural similarity as high-
lighted in red in Figure 6C. ALDH417, ALDH423, and
ALDH440 contain a phenylfuran moiety. ALDH417 and
ALDH440 exhibited even greater similarity that includes a
similar thiazolidinone ring. The benzene ring of the phenyl-
furan is disubstituted in ALDH417 with two chlorine atoms at
the meta and para positions, while ALDH423 and ALDH440
possess a ﬂuorine and chlorine atom at the para position,
respectively (Figure 6C). Inspection of ALDH427 reveals that
the compound has a benzyloxy group that mimics the
phenylfuran of ALDH417. The positions of the oxygen atom
and benzene rings of the benzyloxy moiety mimic the oxygen
atom of the furan and benzene ring of ALDH417, respectively.
Comparison of ALDH417, ALDH427, and ALDH440 reveals
that there are ﬁve bonds between the oxygen atom and the
pyrazole, pyrimidine, and pyran rings of ALDH417, ALDH440,
and ALDH427, suggesting that the rings occupy a similar
position within the binding pocket of ALDH2.
■ DISCUSSION
We conducted a study to explore how enrichment in virtual
screening of chemical libraries is aﬀected by scoring MD
Figure 6. SVMSP rescoring of MD snapshots identiﬁes ALDH2 inhibitors. The dehydrogenase activity was screened by measuring the rate of
increase in the ﬂuorescence of NADH upon propionaldehyde oxidation. (A) Percent activity of ALDH2 in the presence of 50 μM of each of the 111
compounds that were tested; (B) concentration-dependent curves for ﬁve compounds that inhibited in the initial screen; and (C) chemical
structures for the ﬁve compounds (ALDH400, ALDH417, ALDH423, ALDH427, and ALDH440) along with their IC50s for inhibition of ALDH2
dehydrogenase activity.
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structures of protein−compound complexes using a combined
machine learning and statistical potential approach that we
recently developed (SVMSP). We found that using an
ensemble of MD structures showed similar enrichments to
the crystal structure even as the size of the ensemble grew to
250 structures. It is worth mentioning that performance for the
crystal structure was already good for most structures with four
of the eight structures exhibiting ROC-AUC greater than 0.8.
Interestingly, analysis of individual MD structures showed that
there is a large number of snapshots that led to enrichment that
signiﬁcantly exceeded that of the crystal structure. Further
probing revealed that enrichment was not correlated with
structural deviation of the MD snapshots from the crystal
structure. In addition, diﬀerent MD snapshots resulted in
diﬀerent rank-ordering of compounds, suggesting that MD
snapshots may also enhance diversity of the compounds
identiﬁed in virtual screening.
These results prompted us to wonder whether using MD
structures in the training of SVMSP may further improve
enrichment. To test this, we picked two particularly challenging
systems, namely, p38 and CDK2, for which enrichment was not
better than random in the ensemble. In fact, none of the
individual snapshots in p38 exhibited ROC-AUC values that
were better than random, and for CDK2, the majority of the
snapshots had ROC-AUC lower than 0.6. When SVMSP was
trained using compounds docked to MD snapshots
(SVMSPMD) for the negative set, we found a substantial
increase in the enrichment performance, particularly for p38.
The ROC-AUC in the ensemble increased from 0.42 to 0.64
for SVMSPMD and ROC-AUCMAX increased to 0.81 from 0.54
when negative set compounds docked to the crystal structure
were used. Even greater enhancement was obtained when the
positive set was strictly limited to kinases (SVMSPKINASE‑MD),
with ROC-AUCMAX reaching 0.85. In CDK2, similar, but less
pronounced ,increases were observed.
We applied SVMSP scoring to MD snapshots to the
mitochondrial aldehyde dehydrogenase 2 (ALDH2), which
catalyzes the NAD+-dependent oxidation of a broad spectrum
of endogenous and biogenic aldehydes to their corresponding
carboxylic acids. In humans, aldehyde dehydrogenases comprise
a diverse gene family with approximately 20 members in the
human genome sequence.78 ALDH2 may be an important drug
target that has been implicated in drug addiction and other
neurological disorders. We applied SVMSP to rank-order
compounds docked to MD structures of ALDH2. The purpose
of this exercise was not only to put SVMSP scoring of MD
snapshots to the test but also for the discovery of small-
molecule ALDH2 inhibitors that can be pursued in future drug
discovery eﬀorts for this important class of enzyme family. The
screening of 50 000 commercially available compounds against
50 MD snapshots of ALDH2 led to ﬁve compounds that
inhibited the enzyme’s dehydrogenase activity in a concen-
tration-dependent manner. One compound (ALDH423) had
submicromolar activity, while another three (ALDH400,
ALDH427, and ALDH440) inhibited with IC50s lower than
5 μM. Interestingly, three compounds showed structural
similarity. These compounds oﬀer an opportunity to develop
small-molecule inhibitors of the ALDH2 with higher aﬃnity
and selectivity across members of the ALDH family. The
discovery of inhibitors does not validate SVMSP scoring of MD
structures, but, combined with the extensive studies using
validation sets that we have conducted, this work demonstrates
that this approach can result in eﬀective library enrichment.
In summary, we applied our SVMSP scoring approach to
rank-order small molecules docked to conformational ensem-
bles of proteins collected from explicit-solvent MD simulations.
We found that a larger number of MD structures does not
aﬀect enrichment. But MD structures lead to greater diversity
in the conformation of small molecules identiﬁed in virtual
screening. Overall, the performance of SVMSP was better than
other scoring functions for X-ray and MD structures. It is worth
mentioning that we did not assess whether the docking
methods generated accurate poses. This would be diﬃcult to
test particularly for the MD snapshots. However, SVMSP is
trained using high quality protein−ligand crystal structures as
positive set, and we expect that the scoring approach will favor
native-like structures. In our previous work, we have shown that
ﬁltering protein−ligand MD snapshots with SVMSP resulted in
signiﬁcantly better rank-ordering of these complexes based on
the binding aﬃnity.79 Interestingly, MD simulations generated
individual MD snapshots that showed signiﬁcantly better
enrichment than the X-ray structure. Two proteins were
particularly challenging, and both X-ray and MD structures
exhibited random enrichment. To overcome this challenge, we
used MD snapshots to train SVMSP models and discovered a
remarkable increase in performance in enrichment. We also
embarked on an eﬀort to identify high-performance MD
structures a priori from an MD simulation of the apo protein.
We found that it was possible to enrich apo protein MD
structures by scoring randomly selected compounds docked to
these structures using SVMSP. Finally, we put SVMSP
rescoring to the test by rescoring a commercially available
chemical library docked to the ALDH2 enzyme. Enzymology
studies for the top candidates that emerged from a set of 50 000
compounds led to four compounds that had IC50s below 5
μM. These compounds serve as leads for the design and
synthesis of more potent and selective ALDH2 inhibitors.
■ ASSOCIATED CONTENT
*S Supporting Information
Tables S1 and S2 and Figure S1, as referenced in the text. This
material is available free of charge via the Internet at http://
pubs.acs.org.
■ AUTHOR INFORMATION
Corresponding Author
*(S.M.) Mailing address: Department of Biochemistry and
Molecular Biology, Indiana University School of Medicine, 410
W. 10th Street, HITS 5000, Indianapolis, IN 46202. Tel.: (317)
274-8315. Fax: (317) 278-9217. E-mail: smeroueh@iu.edu.
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
The research was supported by the NIH (CA135380 and
AA0197461) and the INGEN grant from the Lilly Endowment,
Inc. (SOM). Computer time on the Big Red supercomputer at
Indiana University is funded by the National Science
Foundation and by Shared University Research grants from
IBM, Inc., to Indiana University.
■ REFERENCES
(1) Shoichet, B. K.; Kobilka, B. K. Structure-based drug screening for
G-protein-coupled receptors. Trends Pharmacol. Sci. 2012, 33, 268−
272.
Journal of Chemical Information and Modeling Article
dx.doi.org/10.1021/ci5002026 | J. Chem. Inf. Model. 2014, 54, 2105−21162113
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